Skip to main content

Advertisement

Table 2 Treatment characteristics

From: Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study

Variable N (%)
Boost approach
SeqB 103 (54.3)
SIB 87 (45.7)
SIB dose and fractionation
PTV dose-tumor (Gy)
  54 Gy/30 fractions 57 (65.5)
  50.4 Gy/28 fractions 30 (34.5)
PTV dose-positive nodes (Gy) (26 pts)
  50.4 Gy/30 fractions 26 (100.0)
PTV dose-negative nodes (Gy)
  45 Gy/30 fractions 53 (60.9)
  42 Gy/28 fractions 34 (39.1)
SeqB dose and fractionation
PTV dose-first sequence
  36 Gy/20 fractions 103 (100)
PTV dose-sequential boost
  23,4 Gy/13 fractions 103 (100)
Chemotherapy regimens
  5-FU + MMC × 2 cycles 159 (83.7)
  5-FU + MMC × 1 cycle 2 (1.0)
  Capecitabine + MMC × 2 cycles 26 (13.7)
  Capecitabine + MMC × 1 cycle 3 (1.6)
  1. Legend, SeqB sequential boost, SIB simultaneous integrated boost, PTV planning target volume, Gy Gray, pts patients, 5-FU 5-fluorouracil, MMC mitomycin C